

# A systems-level analysis highlights microglial activation as a modifying factor in common epilepsies

Andre Altmann<sup>1</sup>  | Mina Ryten<sup>2</sup> | Martina Di Nunzio<sup>3</sup> | Teresa Ravizza<sup>3</sup> |  
 Daniele Tolomeo<sup>3</sup> | Regina H. Reynolds<sup>2</sup> | Alyma Somani<sup>4</sup> | Marco Bacigaluppi<sup>5</sup> |  
 Valentina Iori<sup>3</sup> | Edoardo Micotti<sup>3</sup> | Rossella Di Sapia<sup>3</sup>  | Milica Cerovic<sup>3</sup> |  
 Eleonora Palma<sup>6</sup> | Gabriele Ruffolo<sup>6</sup> | Juan A. Botía<sup>2,7</sup> | Julie Absil<sup>8</sup> |  
 Saud Alhusaini<sup>9,10</sup> | Marina K. M. Alvim<sup>11</sup> | Pia Auvinen<sup>12,13</sup> | Nuria Bargallo<sup>14,15</sup> |  
 Emanuele Bartolini<sup>16,17</sup> | Benjamin Bender<sup>18</sup>  | Felipe P. G. Bergo<sup>11</sup> |  
 Tauana Bernardes<sup>11</sup> | Andrea Bernasconi<sup>19</sup> | Neda Bernasconi<sup>19</sup> |  
 Boris C. Bernhardt<sup>20</sup> | Karen Blackmon<sup>21</sup> | Barbara Braga<sup>11</sup> |  
 Maria Eugenia Caligiuri<sup>22</sup> | Anna Calvo<sup>14</sup> | Chad Carlson<sup>23,24</sup> | Sarah J. A. Carr<sup>25</sup> |  
 Gianpiero L. Cavalleri<sup>9,26</sup> | Fernando Cendes<sup>11</sup> | Jian Chen<sup>27</sup> | Shuai Chen<sup>28,29</sup> |  
 Andrea Cherubini<sup>22</sup> | Luis Concha<sup>30</sup> | Philippe David<sup>8</sup> | Norman Delanty<sup>9,26,31</sup> |  
 Chantal Depondt<sup>32</sup> | Orrin Devinsky<sup>33</sup> | Colin P. Doherty<sup>26,34</sup> | Martin Domin<sup>35</sup> |  
 Niels K. Focke<sup>36,37</sup> | Sonya Foley<sup>38</sup> | Wendy Franca<sup>11</sup> | Antonio Gambardella<sup>22,39</sup> |  
 Renzo Guerrini<sup>16</sup> | Khalid Hamandi<sup>38,40</sup> | Derrek P. Hibar<sup>41</sup> | Dmitry Isaev<sup>41</sup> |  
 Graeme D. Jackson<sup>42,43</sup> | Neda Jahanshad<sup>41</sup> | Reetta Kälviäinen<sup>12,13</sup> |  
 Simon S. Keller<sup>44</sup> | Peter Kochunov<sup>45</sup> | Raviteja Kotikalapudi<sup>18,35,36</sup> |  
 Magdalena A. Kowalczyk<sup>42</sup> | Ruben Kuzniecky<sup>46</sup> | Patrick Kwan<sup>47</sup> |  
 Angelo Labate<sup>22,39</sup> | Soenke Langner<sup>35</sup> | Matteo Lenge<sup>16</sup> | Min Liu<sup>19</sup> |  
 Pascal Martin<sup>36</sup> | Mario Mascalchi<sup>48</sup> | Stefano Meletti<sup>49</sup> |  
 Marcia E. Morita-Sherman<sup>11,50</sup> | Terence J. O'Brien<sup>47,51</sup> | Jose C. Pariente<sup>14</sup> |  
 Mark P. Richardson<sup>25,52</sup> | Raul Rodriguez-Cruces<sup>20,30</sup> | Christian Rummel<sup>53</sup> |  
 Taavi Saavalainen<sup>13,54</sup> | Mira K. Semmelroch<sup>42,43</sup> | Mariasavina Severino<sup>55</sup>  |  
 Pasquale Striano<sup>56</sup> | Thomas Thesen<sup>23</sup> | Rhys H. Thomas<sup>57</sup> | Manuela Tondelli<sup>50</sup> |  
 Domenico Tortora<sup>55</sup> | Anna Elisabetta Vaudano<sup>49</sup> | Lucy Vivash<sup>47,58</sup> |  
 Felix von Podewils<sup>59</sup> | Jan Wagner<sup>60</sup> | Bernd Weber<sup>61</sup> | Roland Wiest<sup>53</sup> |  
 Clarissa L. Yasuda<sup>11</sup> | Guohao Zhang<sup>62</sup> | Junsong Zhang<sup>28,29</sup> | ENIGMA-Epilepsy  
 Working Group | Costin Leu<sup>63,64,65</sup> | Andreja Avbersek<sup>64</sup> | EpiPGX Consortium |  
 Maria Thom<sup>4,65</sup>  | Christopher D. Whelan<sup>9,41</sup> | Paul Thompson<sup>41</sup> |

Andre Altmann, Mina Ryten and Martina Di Nunzio contributed equally.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. *Neuropathology and Applied Neurobiology* published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.

**Carrie R. McDonald<sup>66,67</sup> | Annamaria Vezzani<sup>3</sup> | Sanjay M. Sisodiya<sup>65,68</sup>**

<sup>1</sup>Centre for Medical Image Computing, University College London, London, UK

<sup>2</sup>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK

<sup>3</sup>Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy

<sup>4</sup>Division of Neuropathology, UCL Queen Square Institute of Neurology, London, UK

<sup>5</sup>Department of Neurology, San Raffaele Scientific Institute and Vita Salute San Raffaele University, Milan, Italy

<sup>6</sup>Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy

<sup>7</sup>Departamento de Ingeniería de la Información y las Comunicaciones, Universidad de Murcia, Murcia, Spain

<sup>8</sup>Department of Radiology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium

<sup>9</sup>Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland

<sup>10</sup>Neurology Department, Yale University School of Medicine, New Haven, CT, USA

<sup>11</sup>Department of Neurology, University of Campinas, Campinas, Brazil

<sup>12</sup>Epilepsy Center, Department of Neurology, Kuopio University, Kuopio, Finland

<sup>13</sup>Institute of Clinical Medicine, Neurology, University of Eastern Finland, Kuopio, Finland

<sup>14</sup>Magnetic Resonance Image Core Facility, IDIBAPS, Barcelona, Spain

<sup>15</sup>Centre de Diagnostic Per la Imatge (CDIC), Hospital Clinic, Barcelona, Spain

<sup>16</sup>Pediatric Neurology Unit, Children's Hospital A. Meyer-University of Florence, Florence, Italy

<sup>17</sup>Neurology Unit, USL Centro Toscana, Nuovo Ospedale Santo Stefano, Prato, Italy

<sup>18</sup>Department of Diagnostic and Interventional Neuroradiology, University of Tübingen, Tübingen, Germany

<sup>19</sup>Neuroimaging of Epilepsy Laboratory, Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada

<sup>20</sup>Multimodal Imaging and Connectome Analysis Lab, Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada

<sup>21</sup>Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL, USA

<sup>22</sup>Neuroscience Research Center, Department of Medical and Surgical Sciences, University "Magna Græcia" of Catanzaro, Catanzaro, Italy

<sup>23</sup>Comprehensive Epilepsy Center, Department of Neurology, New York University School of Medicine, New York, New York, USA

<sup>24</sup>Department of Neurology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

<sup>25</sup>Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

<sup>26</sup>FutureNeuro Research Centre, RCSI, Dublin, Ireland

<sup>27</sup>Department of Computer Science and Engineering, The Ohio State University, Columbus, Ohio, USA

<sup>28</sup>Cognitive Science Department, Xiamen University, Xiamen, China

<sup>29</sup>Fujian Key Laboratory of the Brain-like Intelligent Systems, Xiamen, China

<sup>30</sup>Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, Mexico

<sup>31</sup>Division of Neurology, Beaumont Hospital, Dublin 9, Ireland

<sup>32</sup>Department of Neurology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium

<sup>33</sup>Department of Neurology, Langone School of Medicine, New York University, New York, NY, USA

<sup>34</sup>School of Medicine, Trinity College Dublin, Dublin, Ireland

<sup>35</sup>Functional Imaging Unit, Institute of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany

<sup>36</sup>Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany

<sup>37</sup>Department of Clinical Neurophysiology, University Medicine Göttingen, Göttingen, Germany

<sup>38</sup>The Welsh Epilepsy Unit, Department of Neurology, University Hospital of Wales, Cardiff, UK

<sup>39</sup>Institute of Neurology, University "Magna Græcia", Catanzaro, Italy

<sup>40</sup>Cardiff University Brain Research Imaging Centre, School of Psychology, Cardiff University, Cardiff, UK

<sup>41</sup>Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, University of Southern California, Los Angeles, California, USA

<sup>42</sup>The Florey Institute of Neuroscience and Mental Health, Austin Campus, Melbourne, Victoria, Australia

<sup>43</sup>Florey Department of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia

<sup>44</sup>Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK

<sup>45</sup>Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA

<sup>46</sup>Department of Neurology, Zucker Hofstra School of Medicine, New York, New York, USA

<sup>47</sup>Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia

<sup>48</sup>“Mario Serio” Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy

<sup>49</sup>Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, NOCSE Hospital, Modena, Italy

<sup>50</sup>Cleveland Clinic Neurological Institute, Cleveland, USA

<sup>51</sup>The Department of Medicine (The Royal Melbourne Hospital), The University of Melbourne, Parkville, Victoria, Australia

<sup>52</sup>Department of Neurology, King's College Hospital, London, UK

<sup>53</sup>Support Center for Advanced Neuroimaging (SCAN), University Institute for Diagnostic and Interventional Neuroradiology, Inselspital, University of Bern, Bern, Switzerland

<sup>54</sup>Medical Imaging Unit, Central Finland Central Hospital, Jyväskylä, Finland

<sup>55</sup>Neuroradiology Unit, Department of Head and Neck and Neurosciences, Istituto Giannina Gaslini, Genoa, Italy

<sup>56</sup>Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy

<sup>57</sup>Institute of Translational and Clinical Research, Newcastle University, Newcastle upon Tyne, UK

<sup>58</sup>Melbourne Brain Centre, Department of Medicine, University of Melbourne, Parkville, Victoria, Australia

<sup>59</sup>Department of Neurology, University Medicine Greifswald, Greifswald, Germany

<sup>60</sup>Department of Neurology, University of Ulm and Universitäts- and Rehabilitationskliniken Ulm, Ulm, Germany

<sup>61</sup>Institute of Experimental Epileptology and Cognition Research, University of Bonn, Bonn, Germany

<sup>62</sup>Department of Computer Science and Electrical Engineering, University of Maryland, Baltimore County, Baltimore, Maryland, USA

<sup>63</sup>Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA

<sup>64</sup>Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA

<sup>65</sup>Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK

<sup>66</sup>Multimodal Imaging Laboratory, University of California San Diego, San Diego, California, USA

<sup>67</sup>Department of Psychiatry, University of California San Diego, San Diego, California, USA

<sup>68</sup>Chalfont Centre for Epilepsy, Bucks, UK

#### Correspondence

Sanjay M. Sisodiya, Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.

Email: s.sisodiya@ucl.ac.uk

Annamaria Vezzani, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milan, Italy.

Email: annamaria.vezzani@marionegri.it

#### Funding information

FP7 Ideas: European Research Council, Grant/Award Numbers: 602102, 279062; Medical Research Council, Grant/Award Number: MR/L016311/1; National Institutes of Health, Grant/Award Numbers: R01 NS065838, U54 EB020403, R01 NS097719; Fondazione Antonio Carlo Monzino; Associazione Italiana Contro L'Epilessia; Epilepsy Society, UK; Epilepsy Research UK; Katy Baggott Foundation; Department of Health's NIHR Biomedical Research Centres; UCLH Biomedical Research Centre; Leonard Wolfson Doctoral Training Fellowship in Neurodegeneration; Medical Research Council Clinician Scientist Fellowship, Grant/Award Number: MR/N008324/1; Medical Research Council eMedLab Medical Bioinformatics Career Development Fellowship

#### Abstract

**Aims:** The causes of distinct patterns of reduced cortical thickness in the common human epilepsies, detectable on neuroimaging and with important clinical consequences, are unknown. We investigated the underlying mechanisms of cortical thinning using a systems-level analysis.

**Methods:** Imaging-based cortical structural maps from a large-scale epilepsy neuroimaging study were overlaid with highly spatially resolved human brain gene expression data from the Allen Human Brain Atlas. Cell-type deconvolution, differential expression analysis and cell-type enrichment analyses were used to identify differences in cell-type distribution. These differences were followed up in post-mortem brain tissue from humans with epilepsy using Iba1 immunolabelling. Furthermore, to investigate a causal effect in cortical thinning, cell-type-specific depletion was used in a murine model of acquired epilepsy.

**Results:** We identified elevated fractions of microglia and endothelial cells in regions of reduced cortical thickness. Differentially expressed genes showed enrichment for microglial markers and, in particular, activated microglial states. Analysis of post-mortem brain tissue from humans with epilepsy confirmed excess activated microglia. In the murine model, transient depletion of activated microglia during the early phase of the disease development prevented cortical thinning and neuronal cell loss in the temporal cortex. Although the development of chronic seizures was unaffected, the epileptic mice with early depletion of activated microglia did not develop deficits in a non-spatial memory test seen in epileptic mice not depleted of microglia.

**Conclusions:** These convergent data strongly implicate activated microglia in cortical thinning, representing a new dimension for concern and disease modification in the epilepsies, potentially distinct from seizure control.

**KEYWORDS**

cortical thinning, gene expression, MRI, post mortem

## 1 | INTRODUCTION

Significant progress is being made in understanding disease processes in the epilepsies. Many genetic variants causing or associated with rare and common epilepsies have been reported [1, 2], with discovery continuing apace [3]. Numerous direct structural causes of epilepsy have been revealed by brain magnetic resonance imaging (MRI). Several structural abnormalities are now themselves known to have a genetic basis [4]. As a result, the proportion of causally explicable epilepsies is growing rapidly. Conversely, the mechanisms whereby these identified causes promote epileptogenesis and seizures remain obscure for most human epilepsies. Moreover, beyond causation and epileptogenesis, the epilepsies involve many other processes: some lead to clinically apparent consequences, such as developmental delay or memory dysfunction, whereas others, without necessarily obvious symptoms, may be detected only on investigation—cerebellar atrophy is one example. The natural history of any given epilepsy need not be a single linear dynamic from causation to a unique, predictable, final outcome: for example, the epilepsies are associated with shortened longevity (even if seizures stop) [5] and increased risk of particular comorbidities [6]. Known causes per se may not explain all the observed outcomes, suggesting that many epilepsies could be conceptualised as intricate matrices of causation, processes and outcomes [7], with complex inter-dependencies, such as a likely link between reduction in cortical thickness and disease duration [8].

Through the ENIGMA-Epilepsy consortium, we recently showed that across a wide range of common human epilepsies, which are known to have both distinct and shared genetic architecture [2, 3, 9, 10], there are also shared, pan-syndrome, and distinct, syndrome-specific, regional patterns of altered cortical thickness and altered subcortical grey matter volumes [8]. The causes of the structural changes in these epilepsies are not known. The findings suggest that structural losses may reflect an initial insult, subsequent epileptogenesis or progressive neurodegeneration, or some combination, and show robustly that the common epilepsies cannot necessarily be considered entirely benign at the structural level. We sought to identify processes underlying the structural findings.

The pathophysiology of neurological disease has been successfully revealed using powerful combinations of brain MRI findings, regionalised brain-specific gene expression and gene co-expression networks, in a systems biology framework to implicate candidate genes [11–14]. Here, we used the findings from the *in vivo* ENIGMA-Epilepsy imaging study [8] in combination with the post-mortem atlas of gene expression in the brain from healthy subjects, curated by the


### Key points

- Altmann et al. identify microglia as a population of cells likely to be involved in the cortical thinning observed in the common epilepsies.
- They show that experimental microglial depletion prevents cell loss and cortical thinning in an animal model, opening new areas for brain preservation approaches in the epilepsies.
- Seizures and microglia-dependent cortical thinning may be dissociable processes.

Allen Institute [15, 16] to direct interrogation of regionalised brain cell-type composition and generic biological processes that might underlie thickness or volume reductions across the studied epilepsy syndromes. We hypothesised that this approach could suggest disease mechanisms causing the observed structural changes. We further explored the findings with a series of additional experiments in both human and animal tissues. We demonstrated experimentally in a murine model of acquired epilepsy that depletion of the implicated cell type, microglia, can successfully avert cortical thinning and the concomitant neuronal cell loss and cognitive deficit, without modifying spontaneous seizures. Microglia have been shown to have various roles in a few rare, severe human epilepsies. Our new results implicate microglia in the widespread, but largely unstudied, reduction in cortical thickness that accompanies the numerically far more important common human epilepsies and point to the potential for prevention of such thinning by manipulation of microglia.

## 2 | MATERIALS AND METHODS

In order to explore mechanisms underlying cortical thinning in the epilepsies, we designed the study as shown in Figure 1. We obtained statistical maps from a large structural MRI study comparing people with epilepsy to healthy controls conducted by the ENIGMA-Epilepsy consortium [8] (Table S1). To determine cell-type composition differences that spatially correlate with the reported structural changes on MRI, we used a healthy control dataset, the Allen Human Brain Atlas (AHBA), comprising densely sampled gene expression across the cortex [15, 16]. The statistical maps were mapped onto the AHBA using Montreal Neurological Institute (MNI) coordinates. This enabled us to



**FIGURE 1** Analysis overview. (A) The ENIGMA-Epilepsy study identified ‘vulnerable’ and ‘relatively protected’ brain regions indicated in red and blue, respectively (second column; top) [8]. Cortical samples of the AIBS dataset (purple dots; first column, bottom) were marked as either ‘vulnerable’ (red dots) or ‘relatively protected’ (blue dots) depending on their location (second column; middle). Brain cell-type fractions were estimated from the gene expression data, and the differential analysis showed an increased fraction of microglia and endothelial cells in ‘vulnerable’ compared with ‘relatively protected’ regions. Differential gene expression analysis between the two groups followed by pathway analysis confirmed the enrichment for marker genes for microglia as well as immune activation-related pathways. (B) LD score regression estimating the enrichment of immune response eQTL signatures in different epilepsy GWAS finds strong enrichment in disease severity (drug-resistant vs drug-susceptible) but not in disease risk (cases vs controls). eQTL, expression quantitative trait locus; GWAS, genome-wide association study; IFN, interferon; LD, linkage disequilibrium; LPS, lipopolysaccharide

investigate how the spatial distribution of gene expression in the healthy brain correlates with regional vulnerability in the diseased brain. Our primary hypothesis was that cell types causing structural changes observed on human brain MRI could be identified using the design shown in Figure 1A. Briefly, cortical brain regions were classified as vulnerable to, or relatively protected from, cortical thinning based on the previous imaging results [8]. Then two complementary approaches were used to identify cell types with association to reduced cortical thickness: (i) AHBA microarray expression data were de-convolved into cell-type fractions, and these fractions were tested for differences between brain regions; (ii) a standard differential expression analysis was carried out for each gene expression probe, and cell types were identified using enrichment analyses (for details on pre-processing, atlas mapping, quality control and the statistical approach, see Supporting Information Methods, section A). The analysis code for the gene expression analyses is available ([https://github.com/andreamann/AHBA\\_Epilepsy](https://github.com/andreamann/AHBA_Epilepsy)).

We hypothesised that cell types identified from the in silico analysis of data on the spatial distribution of gene expression in the brain from non-epileptic donors would also show compatible differences in spatial distribution in tissue samples obtained from people with epilepsy. Therefore, immunostaining of microglia in post-mortem human brain tissue was carried out to substantiate the cell-type findings from the in silico work. The human post-mortem cases were classified into different epilepsy groups and control groups according to clinical and pathology criteria. The final sample size was based on availability of tissues for certain epilepsies (as characterised by clinical data including electroencephalography [EEG] and MRI) and whether regional tissue paraffin-embedded block samples were available in each case from multiple brain regions (see Supporting Information Methods, section C). Briefly, the labelling index (LI) sums overall microglia presence in terms of cell bodies as well as microglial processes (as cell bodies may not be present in every section, but processes are likely to be important in microglial roles), overcoming issues of microglial

clustering, overlap and aggregation around vessels that can confound individual cell counts. LI also covers all microglial cell types regardless of morphology, size and shape. LI was measured across 14 regions of interest (ROIs) in post-mortem brain tissue derived from 55 individuals, comprising individuals with non-lesional epilepsy (EP-NL,  $n = 18$ ), lesional epilepsy (EP-L,  $n = 21$ ) and non-epilepsy controls (NEC,  $n = 16$ ). No sample size calculations were performed because this was not a discovery sample, but a previous similar study of regional cortical pathology achieved a significant statistical result compared with controls with nine post-mortem cases, whereas this study included 55 individuals [17]. Staining was repeated on the same cases in different immunohistochemistry runs for comparison.

Further, in order to assess whether cortical thinning can be prevented by manipulating microglia, we used a well-established murine model of epilepsy induced by convulsive status epilepticus (SE) provoked by intra-amygdalar injection of kainic acid in C57/BL6N adult male mice (30 g; Charles River, Italy) [18–21]. This model mimics features of mesial temporal lobe epilepsy (MTLE) with hippocampal sclerosis, with neuronal damage also observed in extrahippocampal areas [19–21]. To explore the importance of microglia in brain structural changes and pathologic outcomes, mice were treated with the CSF1R inhibitor PLX3397 in a controlled experiment. We assessed the effect of PLX3397 treatment on cognitive performance using the novel object recognition test (NORT), regional brain volume estimates from post-mortem MRI, abundance of microglia and neurons quantified using immunohistochemistry and Nissl staining, respectively. The sample size was determined a priori based on previous experience with the same epilepsy model [18, 20]. A simple random allocation was applied to assign a subject to a particular experimental group. Group 1: medicated diet (supplemented with PLX3397),  $n = 5$  and placebo (non-medicated) diet,  $n = 5$ ; Group 2: medicated diet (supplemented with PLX3397),  $n = 6$  and placebo (non-medicated) diet,  $n = 5$  (experimental design in Figure S1A). Respective sham mice ( $n = 8$ ) were prepared for behavioural testing and post-mortem analyses. These groups were run 15 days apart. Group 3: placebo diet mice exposed to SE,  $n = 8$  (run in parallel with Group 1,  $n = 4$  and Group 2,  $n = 4$ ) and respective sham mice,  $n = 8$ . Group 3 mice were

prepared to compensate for potential dropouts during the longitudinal experiment (Figure 3C). Limited PLX3397-supplemented diet availability prevented further experiments. To verify the reproducibility of the experimental findings, we compared several EEG measures between the different placebo-diet mouse cohorts, namely, SE onset and duration, temporal distribution of spikes during SE, number and duration of spontaneous seizures. For all these measures, statistical analysis showed that replication was successful. The data were collected by anonymising samples, and the assessor was blinded to diagnosis (for both human tissue and experimental mouse model data). For detailed materials and methods and mouse treatment protocols, see Supporting Information Methods (section D).

### 3 | RESULTS

#### 3.1 | Cortical regions at most risk of reduced thickness are characterised by higher density of microglia and endothelial cells

The AHBA provided gene expression profiles for all cortical ROIs [15, 16]. This gene expression atlas is unique in that from 158 to 348 different brain structures have been sampled from each control individual ( $n = 6$ ), none of whom had epilepsy, covering in total 414 different structures, and that sampling has been precisely mapped to MNI space, enabling linkage of the expression data to external MRI-brain maps in MNI space (see Supporting Information Methods, section A). Thus, the gene expression profiles used in this analysis were highly regionally specified. However, only two out of the six brains have been sampled in both hemispheres: therefore, we restricted our analysis to the left hemisphere, which was available for all subjects [22].

We focussed on the regions where thickness was reduced and sought to identify mechanisms that underlie this cortical regional ‘vulnerability’ to damage; areas without significant loss of thickness compared with controls were considered ‘relatively protected’, remaining like normal cortex. To identify the molecular basis of this

**TABLE 1** Association between inferred cell-type fractions and reduced cortical thickness

Cell type	T-value	P-value	$P_{FDR}$	$P_{perm}$
Astrocytes	2.080608	0.037	0.043	0.17
Endothelial	4.426344	$1.0 \times 10^{-5}$	$7.67 \times 10^{-5}$	0.026
ExNeurons	-3.855666	$1.15 \times 10^{-4}$	$3.08 \times 10^{-4}$	0.051
InNeurons	0.684069	0.49	0.49	0.37
Microglia	4.081655	$4.5 \times 10^{-5}$	$1.79 \times 10^{-4}$	0.032
Oligodendrocytes	2.456355	0.014	0.019	0.053
OPC	2.758717	$5.8 \times 10^{-3}$	0.014	0.068
Unknown	2.690987	0.007	0.011	0.066

Note: Columns represent the cell type, the t-value from the association analysis, the corresponding P-value and the corrected P-value using false discovery rate (FDR). The least column lists a P-value obtained from 1000 permutations of the vulnerable/protected status of 34 regions of interest in the left hemisphere.

Abbreviation: OPC, oligodendrocyte progenitor cell.

regional vulnerability in the broad spectrum of epilepsies, we focussed our analyses on the shared pan-syndrome MRI findings [8]. Of the 34 cortical regions in the left hemisphere profiled within the ENIGMA-Epilepsy dataset, eight were considered vulnerable to reduced cortical thickness, whereas 26 were considered relatively protected [8] (Table S1).

Using linear mixed effects models, we compared these two types of cortical region for significant differences in cell-type fractions, inferred from gene expression using Scaden [23]. We identified increased ratios of endothelial cells ( $T = 4.4$ ;  $P = 1 \times 10^{-5}$ ) and microglia ( $T = 4.1$ ;  $P = 4.5 \times 10^{-5}$ ) in vulnerable regions, along with a decreased ratio of excitatory neurons ( $T = -3.9$ ;  $P = 1.2 \times 10^{-4}$ ) in vulnerable regions (Table 1). We confirmed these cell-type enrichments by a complementary two-step approach. The first step was a gene-wise association screen, showing that, out of 14,138 tested genes, 3182 genes were more highly expressed in vulnerable regions (at  $P_{FDR} < 0.05$ ) and 2223 genes were expressed significantly less in vulnerable regions (at  $P_{FDR} < 0.05$ ; Dataset S1). In the second step, these gene-wise results were subject to threshold-free (i.e., not relying on lists of significantly differentially expressed genes) gene set enrichment analyses using cell-type-specific gene sets from different data sources (Dataset S2). This analysis confirmed the enrichment of endothelial cells and microglia in vulnerable regions and neurons in protected regions. We noted that both analyses provided qualitatively the same result when using all 1628 AHBA samples from both hemispheres, where 18 of 68 ROIs were considered vulnerable (Table S2; Figure S15). Thus, regions vulnerable to cortical thinning were characterised by elevated proportion of microglia and endothelial cells.

### 3.2 | Selected processes and microglial signatures are implicated amongst genes associated with reduced cortical thickness

Using our gene-level association results, we next investigated the biological processes that could underpin regional differences in vulnerability to reduced cortical thickness in epilepsy. In the first instance, we investigated enrichment of differentially expressed genes in Gene Ontology (GO) terms and Kyoto Encyclopaedia of Genes and Genomes (KEGG) and REACTOME pathways using a threshold-free approach based on the area under the receiver operator characteristics curve (AUC) [24]. Amongst genes with higher expression in relatively protected cortical regions, the most significant terms we identified related to RNA processing (REACTOME: RNA polymerase II transcription,  $AUC = 0.429$ ,  $P_{FDR} = 1.19 \times 10^{-11}$ ) and synaptic function (GO: postsynaptic specialisation organisation,  $AUC = 0.270$ ,  $P_{FDR} = 3.95 \times 10^{-4}$ ; Dataset S3). Conversely, amongst genes with higher expression in vulnerable cortical regions, the most significant terms related to electron transport (GO: electron transport chain,  $AUC = 0.74$ ,  $P_{FDR} = 3.45 \times 10^{-18}$ ) and immune function and regulation (REACTOME: innate immune system,  $AUC = 0.59$ ,  $P_{FDR} = 1.46 \times 10^{-15}$ ; GO: antigen processing and presentation,

$AUC = 0.65$ ,  $P_{FDR} = 7.98 \times 10^{-13}$ ; Dataset S3), the latter being consistent with our results obtained using cell-specific gene sets. There was also strong enrichment for the KEGG pathways related to neurodegenerative diseases (Alzheimer's disease:  $AUC = 0.65$ ,  $P_{FDR} = 3.53 \times 10^{-6}$ ; Parkinson's disease:  $AUC = 0.75$ ,  $P_{FDR} = 4.55 \times 10^{-12}$ ; Huntington's disease:  $AUC = 0.66$ ,  $P_{FDR} = 1.80 \times 10^{-7}$ ). Moreover, this approach also enabled us to obtain more specific process-related information and suggested the importance of the interferon gamma signalling pathway (GO: response to interferon gamma,  $AUC = 0.597$ ,  $P_{FDR} = 1.42 \times 10^{-3}$ ; GO: interferon gamma-mediated signalling pathway,  $AUC = 0.621$ ,  $P_{FDR} = 6.71 \times 10^{-3}$ ; Dataset S3).

A number of cell types showed enrichment in vulnerable regions. But both cell-type analysis and the observed pathway enrichments implicated microglia and immune processes, respectively, prompting us to investigate microglia in more detail, given existing evidence for a role for microglia in epilepsy [25] and in neurodegeneration in general [26]. More precisely, because microglia can exist in a range of activation states within the context of epilepsy [25], we sought to identify the microglial cell states of greatest importance in reduced cortical thickness. We collated gene signatures for distinct microglial states from the existing literature and also inferred signatures of microglial state through co-expression network analyses (see Supporting Information Methods, section A). Although there were significant overlaps in gene membership across the 16 microglial signatures used (Figure S2), each of the gene lists was distinct. We identified a significant enrichment for 13 of the 16 signatures with genes overexpressed in vulnerable cortex. This included the microglial signature generated by Srivastava et al. [27] ( $AUC = 0.68$ ,  $P_{FDR} = 1.45 \times 10^{-12}$ ; Dataset S4), which was positively correlated with seizure frequency in a particular mouse model of chronic epilepsy. Strong enrichments were also identified for an inferred human microglial signature enriched for type 1-like microglial markers ( $AUC = 0.73$ ,  $P_{FDR} = 7.27 \times 10^{-18}$ ; grey60; Dataset S4), as well as signatures for aged, late activation and de-activated microglia. However, we saw little evidence for enrichment within signatures of early activation ('Early Response' signature [28],  $AUC = 0.53$ ,  $P_{FDR} = 0.062$ ). Similar microglial states have recently been implicated in various forms of chronic neurodegeneration [28–30], but more data are needed to definitively determine whether similar underlying processes and microglial states are indeed involved.

### 3.3 | Genetic evidence supports immune activation as a modifying, but not causal, factor in the common epilepsies

In the ENIGMA-Epilepsy imaging study, region-specific reduced cortical thickness across the common epilepsies was correlated with disease duration and age of onset of epilepsy [8]. Given that the analyses of gene expression data from healthy donors described above suggest the importance of microglia responses in vulnerability to reduced cortical thickness, we hypothesised that genetic variants affecting

microglial responses would also impact upon the severity of epilepsy. Although no microglial expression quantitative trait locus (eQTL) dataset exists to date, eQTL analyses have been performed using monocytes at rest, and also monocytes treated with interferon  $\gamma$  (IFN- $\gamma$ ) or lipopolysaccharide (LPS) [31]. We postulated that these eQTLs would be enriched for heritability of risk loci for epilepsy that is drug resistant (one surrogate for disease severity) but not for epilepsy per se. To investigate this, we used genome-wide association study (GWAS) data on epilepsy susceptibility [2] and separate GWAS data on the phenotype of drug-resistant epilepsy from the EpiPGX consortium ([www.epipgx.eu](http://www.epipgx.eu)). Using linkage disequilibrium (LD) score regression, we sought enrichment in heritability for these phenotypes within state-specific monocyte eQTLs [31] (Supporting Information Methods, section B). We found no significant enrichment in the heritability of epilepsy in this form of annotation, suggesting that susceptibility to common epilepsies is less likely to be driven by immune processes (Figure 1B, Table 2). However, eQTLs regulating the response to IFN- $\gamma$  were highly enriched for drug-resistant epilepsy vs drug-responsive epilepsy loci ( $P = 0.00045$ ;  $P_{FDR} = 0.0095$ , Table 2). This result was particularly striking given the small size of the EpiPGX drug-resistant epilepsy GWAS (2423 drug-resistant cases vs 1626 drug-responsive cases). Thus, we provide genetic evidence in support of microglial-mediated responses as a modifying factor in severity of epilepsy, but not its susceptibility.

### 3.4 | Widespread regionalised over-representation of microglia is present in brain tissue from people with epilepsy

On the basis of the analyses of regional gene expression patterns in healthy brains above, we hypothesised that brain tissue from individuals with various forms of epilepsy would have regionalised higher densities of microglia as compared with tissue from non-epilepsy controls and that this would be apparent beyond the context of acute seizure activity. Using Iba1 immunolabelling, we found that single ramified microglia and processes were found throughout the cortex; scattered perivascular macrophages were also labelled (Figure 2A). Enlarged and more complex/branching microglia, focal aggregates and

amoeboid/macrophage forms were noted in some ROIs (Figure 2A). Consistent with our hypothesis, the Iba1 LI was significantly higher in all epilepsy (EP-NL and EP-L together) than NEC for all ROIs ( $P = 4.0 \times 10^{-13}$ ) and for both subgroup comparisons (EP-NL [ $P = 3.7 \times 10^{-13}$ ] and EP-L [ $P = 3.5 \times 10^{-13}$ ]) against NEC. Regional differences were noted within the epilepsy groups and for individual ROIs compared between epilepsy and control groups (see Figures 2 and S16 and Table S3). We noted that the Iba1 LI was similar across EP-NL, EP-L and NEC in BA17, as compared with pulvinar and BA22 where the Iba1 LI was higher in EP-NL and EP-L groups than in NEC. Thus, these results are consistent with the view that there is an over-representation of microglial footprint in brain tissue from people with chronic epilepsy and that such microglial responses may occur in a regionally specific manner. This observation was supported by evidence of region-specific microglia expansion in epileptic mice as reflected by the increased number of Iba1-positive cells in entorhinal cortex but not in perirhinal cortex (Figure S3). Moreover, in sham mice, we also observed that the temporal cortices have a higher microglia density than the hippocampus, denoting regionalised microglia enrichment at baseline (Figure S3).

### 3.5 | Experimental evidence supports microglial activation as a modifying factor for cortical thickness in a mouse model of acquired epilepsy

The analyses so far have shown (i) elevated expression of microglia-related genes in brain regions, deemed 'vulnerable' from the ENIGMA-Epilepsy imaging study, in healthy brains and (ii) widespread regionalised over-representation of microglia in brain tissue from people with epilepsy compared with tissue from non-epileptic controls. To provide proof-of-concept evidence causally linking microglia activation to cortical thinning, we used a mouse model of acquired epilepsy where convulsive seizures originate and spread in the limbic system and also involve the neocortex [18–21]. Spontaneous seizures develop a few days after the acute insult (mean  $\pm$  SEM, onset,  $6.2 \pm 0.5$  days,  $n = 21$  mice of Figure 3C) and recur for months (Figure S4B,C) and are drug resistant [20]. Microglia are


**TABLE 2** Results from stratified linkage disequilibrium score regression estimating the enrichment of immune response eQTL signatures (rows) in different epilepsy GWAS (columns)

eQTL type	GWAS					
	ILAE (epilepsy vs HC)		Drug-resistant vs HC		Drug-resistant vs drug responders	
	<i>P</i>	<i>P</i> <sub>FDR</sub>	<i>P</i>	<i>P</i> <sub>FDR</sub>	<i>P</i>	<i>P</i> <sub>FDR</sub>
Naïve monocytes	$8.73 \times 10^{-2}$	$1.63 \times 10^{-1}$	$3.43 \times 10^{-2}$	$8.12 \times 10^{-2}$	$2.85 \times 10^{-3}$	<b><math>2.00 \times 10^{-2}</math></b>
IFN- $\gamma$ -treated	$1.56 \times 10^{-2}$	$8.12 \times 10^{-2}$	$5.09 \times 10^{-2}$	$1.06 \times 10^{-1}$	$4.53 \times 10^{-4}$	<b><math>9.52 \times 10^{-3}</math></b>
LPS-treated (2 h)	$1.43 \times 10^{-1}$	$2.32 \times 10^{-1}$	$2.70 \times 10^{-1}$	$3.90 \times 10^{-1}$	$3.48 \times 10^{-2}$	$8.12 \times 10^{-2}$
LPS24-treated (24 h)	$3.17 \times 10^{-2}$	$8.12 \times 10^{-2}$	$1.97 \times 10^{-2}$	$8.12 \times 10^{-2}$	$1.27 \times 10^{-3}$	<b><math>1.33 \times 10^{-2}</math></b>

Note: Bold font marks significant enrichments at  $P_{FDR} < 0.05$ .

Abbreviations: eQTL, expression quantitative trait locus; GWAS, genome-wide association study; HC, healthy controls; IFN- $\gamma$ , interferon  $\gamma$ ; ILAE, International League Against Epilepsy study (The International League Against Epilepsy Consortium on Complex Epilepsies, 2014); LPS, lipopolysaccharide.






**FIGURE 2** Presence of excess activated microglia in post-mortem brain tissue from people with epilepsy. (A) High magnification of morphological types of Iba1-labelled cells including (bottom row; left to right) ‘rod’ cells, ramified microglia, perivascular macrophage and amoeboid forms. Fixation time in illustration of ramified microglia was 467 days (bar = 30 microns). Top row shows Iba1 labelling in randomly selected regions from cases in the study (representing all three groups) with a range of immunostaining quantified from 0.5% to 6.5% field fraction with progressive increase in complexity, number and size of ramified microglial (all taken at  $\times 20$ ). (B) Scatter graph of all data points from 709 sections including all brain regions showing mean and standard deviation for labelling index in the four main groups: Epilepsy-ALL (EP-ALL), Epilepsy Non-Lesional (EP-NL), Epilepsy-Lesional (EP-L) and non-epilepsy controls (NEC). EP-ALL, EP-NL and EP-L are all significantly greater than NEC (\* respective  $P$ -values:  $4.0 \times 10^{-13}$ ,  $3.7 \times 10^{-13}$ ,  $3.5 \times 10^{-13}$ ). (C) Iba1 immunolabelling shown in 10 Brodmann areas and thalamus in each hemisphere, colour coded for the mean percentage labelling index in the three groups as in (B). (D) Scatter graph of the mean Iba1 LI in the same Brodmann areas and thalamus (averaged over both hemispheres) in the four groups as in (B)

morphologically activated (CD11b-positive area, hippocampus:  $\text{mm}^2$ , sham,  $0.09 \pm 0.01$ ; 1 week after SE,  $1.67 \pm 0.48$ ,  $P = 0.0002$ , Mann-Whitney test;  $n = 10$ –11 mice) and proliferate by 2.0-fold on average within 1 week after SE as assessed in a different cohort of mice by analysis of Iba1-positive cells in the forebrain (number of cells, hippocampus: sham,  $614.4 \pm 7.1$ ; 1 week after SE,  $1347 \pm 68.6$ ,  $P = 0.0011$ , Mann-Whitney test;  $n = 10$ –11 mice).

First, we studied whether the thickness and volume of selected cortical brain regions were reduced, and those of the lateral ventricles increased (directions of change as predicted by the ENIGMA-Epilepsy findings in humans) in placebo (non-medicated)-diet-fed epileptic mice ( $n = 10$ ) vs sham mice (not exposed to SE,  $n = 16$ ) as assessed by post-mortem MRI (experimental design in Figure S1A). In the post-mortem MRI analysis (Figures 3A, S5 and S6), we also included additional placebo-diet-fed epileptic mice ( $n = 8$ ) run in parallel with mice depicted in Figure 3C ( $n = 10$ ). These additional mice were video-EEG monitored only in the terminal disease phase (Days 55–90), and their

seizure frequency ( $0.91 \pm 0.26$ ,  $n = 8$ ) was similar to mice depicted in Figure 3C ( $1.65 \pm 0.75$ ,  $n = 10$ ;  $P = 0.41$  by the Mann-Whitney test). These additional epileptic mice were also included in the histopathological brain analysis (Figure 3B) and for behavioural testing (Figure 3D). We found that the lateral ventricles were enlarged by twofold ( $P = 0.0006$  by analysis of variance [ANOVA] followed by Tukey’s test; Figure S5A): this effect was associated with a significant reduction in the volume of the entorhinal ( $P = 0.043$ ; Figure S5E) and perirhinal ( $P = 0.025$  by ANOVA followed by Tukey’s test; Figure S5F) cortices. No significant changes were observed in other brain areas such as the hippocampus, caudato-putamen and the thalamus, although their average volumes trended lower than the corresponding values in sham mice (Figure S5B–D). Notably, a significant reduction in the thickness of entorhinal ( $P = 0.0001$  by ANOVA followed by Tukey’s test; Figure 3A) and perirhinal ( $P = 0.046$  by ANOVA followed by Tukey’s test; Figure S6) cortices was also measured in the same mice.



**FIGURE 3** Legend on next page.

Next, we measured brain region volumes and cortical thickness in mice fed with medicated diet, supplemented with PLX3397, in order to deplete microglia by >90% (Figure S7) during the initial disease development (i.e., until Day 7 after spontaneous seizure onset; experimental design in Figure S1A). Importantly, this decrease in microglia was induced transiently, because microglia re-populated the forebrain within 1 week after switching mice to a placebo non-medicated diet [32]. This protocol was followed in order to assess the impact of microglia activation in the initial phases of the disease on the structural brain changes detected in the epileptic mice. We found that the decrease in thickness of the entorhinal cortex of epileptic mice under placebo diet vs sham mice was prevented in mice that were depleted of microglia in the early disease phase ( $P = 0.022$  vs placebo by ANOVA followed by Tukey's test; Figure 3A). This indicates that early microglia depletion prevented the entorhinal cortical thinning determined in the chronic disease phase. Microglia depletion did not affect the thinning of the perirhinal cortex (Figure S6) or the ventricle and subcortical volume changes occurring in epileptic mice (Figure S5). Evaluation of neuronal cell number in the entorhinal cortex of epileptic mice receiving placebo diet showed a significant decrease in both neuronal cell density ( $P = 0.0001$  vs sham by ANOVA followed by Tukey's test; Figure 3B) and their average cell body size ( $P = 0.037$  vs sham by ANOVA followed by Tukey's test; Figure 3B). The reduction in cell density, but not of the average cell body size, in epileptic mice was prevented by microglia depletion in the early disease phase ( $P = 0.006$  vs placebo diet by ANOVA followed by Tukey's test; Figure 3B). Similarly, microglia depletion affected the reduction in discrimination index (a measure of non-spatial memory deficit dependent

on entorhinal cortex function) [33] observed in epileptic mice fed with placebo diet ( $P = 0.0004$  epileptic mice vs sham by ANOVA followed by Tukey's test;  $P = 0.049$  epileptic mice on the PLX3397 diet vs placebo diet by the Mann-Whitney test) (Figure 3D). The total exploration time of objects during the familiarisation phase did not differ in the various experimental groups (sham,  $24.07 \pm 2.6$  s; SE + placebo,  $28.4 \pm 4.7$  s; SE + PLX3397,  $29.7 \pm 5.9$  s;  $P = 0.25$  sham vs placebo;  $P = 0.5$  SE + placebo vs SE + PLX3397). Notably, microglia depletion in the early disease phase did not modify the onset, duration and severity of SE (Figure S4A). Moreover, both frequency and duration of spontaneous seizures were unaltered by early microglia depletion as compared with placebo non-medicated diet-fed mice (Figure 3C; Figure S4C vs B).

## 4 | DISCUSSION

The epilepsies are complex conditions with multiple facets including various causes, differing responses to treatment and unpredictable outcomes. Most attention has been paid to causation and processes of epileptogenesis across the broad constituent spectrum of syndromes. In contrast, disease progression has not been a primary focus of research even though for some rare epilepsies (the developmental and epileptic encephalopathies [DEE]), the window of opportunity to ameliorate disease may be open for longer than expected, as disrupted patterns of gene expression last into adulthood [34]. Here, we show that across the broad spectrum of the more common epilepsies (specifically excluding DEE), gene expression-predicted microglial density

**FIGURE 3** Effects of microglia depletion in the early disease phase on entorhinal cortex thickness and neuronal cell loss and on cognitive deficit in epileptic mice. The experimental design is depicted in Figure S1A. Grey symbols represent sham ( $n = 6-8$ ) and epileptic mice fed with placebo diet ( $n = 8$ ) run in parallel with experimental mice of (C) (see text for details). (A) Box-and-whisker plots depicting median, minimum, maximum and single values related to the entorhinal cortex thickness, as assessed by quantitative post-mortem magnetic resonance imaging (MRI) analysis performed in epileptic mice at the end of electroencephalography (EEG) monitoring (placebo are mice fed with non-medicated diet;  $n = 18$ ; PLX3397 are mice fed with medicated diet supplemented with PLX3397;  $n = 7$ ) and in sham mice (not exposed to status epilepticus;  $n = 16$ ). MRI images depict representative slices showing the region of interest (ROI) used to quantify the cortical thickness. Four mice in the PLX3397 group did not undergo MRI analysis, and therefore, they were not included in the subsequent histological (B) and behavioural analyses (D). The white line within the ROI was manually drawn to measure the cortical thickness.  $**P = 0.0001$  vs sham;  $^{\circ}P = 0.022$  vs placebo by analysis of variance (ANOVA) followed by Tukey's test. Scale bar: 1 cm. (B) Representative Nissl-stained sections (top row) of the entorhinal cortex in the experimental groups (top row; sham,  $n = 14$ ; placebo,  $n = 15$ ; PLX3397,  $n = 7$ ), and the relative quantification of the number and the average size of Nissl-stained neurons (bottom row). Two sham and three placebo mice were excluded from the analysis due to poor quality of Nissl staining. Data are shown by box-and-whisker plots depicting median, minimum, maximum and single values  $*P = 0.0037$ ,  $**P = 0.0001$  vs sham;  $^{\circ\circ}P = 0.006$  vs placebo diet by ANOVA followed by Tukey's test. Scale bars: 100  $\mu\text{m}$ . (C) Box-and-whisker plots depicting median, minimum, maximum and single values of the number of spontaneous seizures/day and their average duration during Days 1-7, 8-15 and 55-90 from epilepsy onset (Day 1) in the placebo ( $n = 10$ ) and PLX3397-supplemented diet ( $n = 11$ ) experimental groups (protocol in Figure S1A). Friedman's two-way nonparametric ANOVA ( $P = 0.041$ ) followed by post hoc multiple comparisons test with Bonferroni correction:  $P$ -values for Number of seizures/day:  $P = 0.363$ , Days 1-7;  $P = 0.339$ , Days 8-15;  $P = 0.965$ , Days 55-90;  $P$ -values for Seizures duration:  $P = 0.799$ , Days 1-7;  $P = 0.325$ , Days 8-15;  $P = 0.262$ , Days 55-90. Outliers were identified only for the Number of seizures/day in the placebo group ( $n = 1$  in Days 1-7) and in the PLX3397 group ( $n = 2$  in Days 8-15 and  $n = 2$  in Days 55-90); however, their omission did not change the results of the primary statistical analysis; therefore, the values were not removed from the corresponding dataset ( $P$ -values for sensitivity analysis:  $P = 0.831$ , Days 1-7;  $P = 0.375$ , Days 8-15;  $P = 0.084$ , Days 55-90). (D) Novel object recognition test (NORT) in epileptic mice fed with placebo- ( $n = 13$ ) or PLX3397-supplemented diet ( $n = 7$ ), and sham controls ( $n = 13$ ). Three sham and five placebo diet epileptic mice were excluded from the analysis because they showed a total exploration time < 6 s during the familiarisation phase. Memory was evaluated by measuring the discrimination index, which was calculated as time spent (seconds) exploring the familiar (F) and the novel (N) object as follows:  $(N - F)/(N + F)$ . Data are shown by box-and-whisker plots depicting median, minimum, maximum and single values, differences significant at  $**P = 0.0004$  vs sham by ANOVA followed by Tukey's test;  $*P = 0.049$  vs placebo by the Mann-Whitney test

spatially correlated with reduced cortical thickness; the related genes newly implicate innate immunity and, particularly, microglial activation, as contributors to the underlying cause of cortical thinning. We also show that this molecular signature of innate immunity activation is significantly enriched for a gene set already causally linked to seizure frequency in a mouse model of chronic epilepsy [27], though we note our model differs from the model in that study. Further, our data add new evidence supporting the general concept that microglial activation is associated with at least some of the structural changes seen in brain areas involved in seizure circuitry, in that microglial depletion in mice early during disease development can directly prevent associated cortical thinning in the entorhinal cortex. Notably, microglial depletion in mice also prevented neuronal cell loss in the entorhinal cortex, and this neuroprotective effect was associated with improvement of cognitive deficit measured by the non-spatial memory test, that is sensitive to entorhinal cortex function [33].

Furthermore, we tested the hypothesis that microglial/monocyte activation is a key modulator of the severity of epilepsy using both genetic and functional approaches. We used the availability of GWAS data for resistance to anti-epileptic drug treatment, a marker of disease severity, to investigate enrichment in heritability at genetic loci already known to influence the expression of genes involved in monocyte activation. We find a highly significant enrichment in the heritability of epilepsy severity amongst these immunomodulatory loci, despite the absence of a significant enrichment for heritability of epilepsy per se. Finally, in keeping with these observations, experimental microglial depletion timed to coincide with a period of epileptogenesis in a murine model of acquired epilepsy can prevent regionalised cortical thinning, but does not influence the eventual development of seizures themselves in our model. Data from the experimental model also demonstrate that the cortical thinning is at least partly due to reduced neuronal cell density and average neuronal size: reduction of neuronal density can be prevented by appropriately timed microglial depletion while neuronal size changes were not rescued, which may explain the observation that entorhinal volume changes are not completely prevented by microglial depletion. We, and others [35–40], find that activated microglia are present in excess in brain tissue from people with epilepsy, compared with brain tissue from healthy controls, providing evidence for translation to human epilepsies of our assertions from the experimental model data. We selected Iba1 as a robust immunomarker for microglia in formalin-fixed tissue [41]. Like HLA-DR and CD68, Iba1 labels all phenotypes of microglia from ramified and amoeboid forms to macrophages and is therefore suited to structural studies of normal cortex in the absence of focal pathology [42]. We recently reported increased Iba1 labelling in central autonomic cortical regions in SUDEP, which also associated with increased seizures prior to death [43]. Together, these findings separate important processes occurring in the course of the epilepsies and incriminate potentially modifiable microglial activation states in the hitherto largely ignored feature of cortical thinning in the common human epilepsies. Unsurprisingly, our results also suggest that other factors are likely to be involved, which we have not explored further yet.

Importantly, we note as limitations that we assume a high degree of similarity in the genetics of gene expression in monocytes and microglia and that the clue to the possible role for microglial activation in cortical thinning came from a cross-sectional study of chronic human epilepsy: although reduced cortical thickness correlated with disease duration [8], we could not distinguish whether the structural difference had developed at disease onset (e.g., with causation), during epileptogenesis, during the course of the disease or a combination of these epochs. Our multimodal data, and especially the experimental model results, allow us to begin to address this question. Notably, we used spatially resolved whole-brain gene expression data from healthy controls, rather than from the brains of people with epilepsy specifically to avoid confounding by secondary effects: some such effects (e.g., compensatory changes) may be worth exploring, but that was not our purpose here. The murine model in our study relates to early processes in epileptogenesis and shows a clear separation for microglial roles in cortical thinning and seizure occurrence, whereas data from other models relate to the chronic disease state and show an effect of microglial manipulation on seizure frequency in that chronic state [27, 44] (cortical thinning was not assessed in those models). The experimental and human data are not directly compatible, and we cannot test hypotheses arising from the chronic mouse model in data from human ENIGMA-Epilepsy. However, taken together, the data suggest that microglia may have multiple modifying roles during epileptogenesis and progression of disease across common human epilepsies, though we find no evidence that they contribute to the actual occurrence of these common forms of epilepsy (from either our human or murine data). That seizure frequency and cortical thinning may be separable processes adds to important epidemiological evidence that seizure frequency is not the only contributor to morbidity in people with a history of epilepsy [5]. Microglia have many roles in specific types of epilepsy, demonstrated clearly in a variety of animal models. Such roles include phagocytosis, which may link consumption of synapses with cognitive changes in long-term active epilepsy [45], providing another possible mechanism for actual loss of brain volume in epilepsy: ‘time is brain’ [46].

Dysregulation of innate immunity is considered possibly to contribute to brain pathology and seizures in some severe human epilepsies. Microglial activation is seen in Rasmussen’s encephalitis and in tissue from epilepsies due to hippocampal sclerosis and mesial temporal lobe sclerosis, focal cortical dysplasia and tuberous sclerosis [35–39]. The latter two conditions are known to have genetic, rather than inflammatory, causes, but the extent of microglial activation in the chronic disease phase correlates with severity (seizure frequency) and disease duration in these studies [35, 39] and not just cause, pointing again to distinctions between processes related to the initial cause (e.g., genetic disorder) and others that manifest during active disease. Importantly, resected human brain tissue is only available from a few cases of a few types of epilepsies (mostly surgical specimens from MTL and focal cortical dysplasia [47]), so that it is impossible to otherwise evaluate the role of microglia using neuropathological data in the majority of common human epilepsies, from which brain tissue cannot be obtained in life. Brain imaging in animal

models using a label (TSPO) for microglial activation shows dynamic upregulation during epileptogenesis, with persistent, although declining, activity in the chronic phase and correlation with spontaneous seizures [48]; in chronic human temporal lobe epilepsy, there is increased TSPO binding ipsilateral and contralateral to seizure foci [49] and in the interictal phases [50]. Using immunolabelling, we demonstrate that there is over-representation of activated microglia in human and experimental brain tissue, compared with controls. The animal data also highlight that microglia expansion in epileptic mice occurs in the entorhinal but not in perirhinal cortex, and this effect is mirrored in the rescue of cortical thinning by microglia depletion (Figure S3). However, neither TSPO imaging nor neuropathological study is realistically applicable to large numbers of people with epilepsy, especially common epilepsies, while MRI is providing a readily available means of evaluating clinical translation of the implications of our findings. We propose, using MRI-derived patterns and correlation with gene expression, that activated microglia-associated functions drive the important, but as yet largely neglected, phenotype of cortical thinning in a broad swathe of common human epilepsies. Subsequent experimental intervention in an animal model suggests that early manipulation of microglia has the capacity to rescue disease-related cortical thinning, neuronal cell loss and cognitive deficits, opening up new areas for attention and treatment in common human epilepsies. We note that other cell types and processes are also implicated: these also need consideration, and suggest the possibility of multiple players in cortical thinning: we have focussed on one cell type, which does not diminish the potential utility of its manipulation. Other processes and cell types will be the subject of future investigations.

Our results point to important roles for neuroinflammatory pathways and potentially specific molecular actors, such as IFN- $\gamma$ . However, the diversity of microglial states and functions, and the complex, dynamic, interactions between neurons, astroglia and microglia, that at the very least can promote epileptogenesis [25] have yet to be fully resolved. Clinical translation of our key observation of the widespread role of microglial activation across the breadth of types of epilepsy into therapeutic options to prevent irreversible loss of brain substance will require definition of the time course of thinning in the different types of epilepsy. Translation will also require the development of safe, effective and tolerable treatments that target precise mechanisms without compromising immune surveillance of brain tissue, a need across diverse neurological disorders [51].

#### ACKNOWLEDGEMENTS

We thank Angela Richard-Londt, Francesca Launchbury and Matthew Ellis for assistance with human neuropathology data collection; Mojgansadat Borghei, Ilaria Lagorio and Yi Yao for assistance with data collection; and Rafal Kaminski and Jonathan van Eyl for helpful discussions. We thank Dr L. Porcu (Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy) for statistical advice.

A. Altmann holds a Medical Research Council eMedLab Medical Bioinformatics Career Development Fellowship. This work was supported by the Medical Research Council (grant number

MR/L016311/1). M.R. holds a Medical Research Council Clinician Scientist Fellowship (grant number MR/N008324/1). R.H.R. was supported through the award of a Leonard Wolfson Doctoral Training Fellowship in Neurodegeneration. The work was supported by grants from the European Union (7th Framework Programme [FP7 Ideas: European Research Council] Grants 279062, EpiPGX and 602102, EPITARGET). This work was partly undertaken at UCLH Biomedical Research Centre/UCL, which received a proportion of funding from the Department of Health's NIHR Biomedical Research Centres funding scheme. The Epilepsy Society through the Katy Baggott Foundation supports the Epilepsy Brain and Tissue Bank at UCL, and Epilepsy Research UK (ERUK) supports the Corsellis Epilepsy brain collection. The work was also supported by the Epilepsy Society, UK (C.L., S.M.S.), Associazione Italiana Contro L'Epilessia (FIRE-AICE) and Fondazione Antonio Carlo Monzino (A.V.) and National Institutes of Health (NIH) Grants R01 NS097719 (M.E.M.), U54 EB020403 (P.T.) and NIH/NINDS R01 NS065838 (C.R.M.).

#### CONFLICT OF INTEREST

C.D.W. is now an employee of Biogen Research and Early Development (Cambridge, MA 02142, USA).

#### ETHICS STATEMENT

The project has ethical approval (under NRES 17/SC/0573), and post-mortem epilepsy cases had research consent, compliant with the UK Human Tissue Act 2014. Furthermore, in accordance with the ARRIVE guidelines, procedures involving animals and their care were conducted in conformity with the institutional guidelines that are in compliance with national (D.L. n.26, G.U. March 4, 2014) and international guidelines and laws (EEC Council Directive 86/609, OJ L 358, 1, December 12, 1987, Guide for the Care and Use of Laboratory Animals, U.S. National Research Council, 1996) and were reviewed and approved by the intramural ethical committee.

#### AUTHOR CONTRIBUTIONS

A. Altmann, M.R., A.V. and S.M.S. conceived and designed the research and wrote the paper. Authors J.A. to J.Z. and C.D.W., P.T., C.R.M. and S.M.S. contributed to generation and analysis of human neuroimaging data as part of ENIGMA-Epilepsy working group, which is co-ordinated by C.R.M. and S.M.S., with overall leadership of the ENIGMA consortia by P.T. A. Altmann analysed AIBS data. C.L. and A. Avbersek and EpiPGX generated and analysed the human drug resistance GWAS data. J.A.B. generated co-expression network data. R.H.R. performed EWCE analyses. A.S. and M.T. generated and analysed the human post-mortem data. M.D.N., T.R., D.T., M.B., V.I., E.M. and A.V. generated and analysed the murine experimental model data. All authors contributed to the editing of the manuscript.

#### DATA AVAILABILITY STATEMENT

The complete normalised microarray gene expression data from the Allen Institute for Brain Science that support the findings of this study are available from the institute's website at <http://human.brain-map.org/static/download>. The eQTL summary statistics on state-specific

monocytes that support the findings of this study are available in the supplementary tables at DOI: 10.1126/science.1246949. The summary results from the EpiPGX GWAS data that support the findings of this study are available from <http://www.epigad.org>. Data from the experimental model that support the findings of this study are available from the corresponding author(s) upon reasonable request.

## ORCID

Andre Altmann  <https://orcid.org/0000-0002-9265-2393>

Rossella Di Sapia  <https://orcid.org/0000-0001-7481-5198>

Benjamin Bender  <https://orcid.org/0000-0002-3205-4631>

Mariasavina Severino  <https://orcid.org/0000-0003-4730-5322>

Maria Thom  <https://orcid.org/0000-0001-7712-2629>

## REFERENCES

- Orsini A, Zara F, Striano P. Recent advances in epilepsy genetics. *Neurosci Lett*. 2018;667:4-9.
- The International League Against Epilepsy Consortium on Complex Epilepsies. Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. *Lancet Neurol*. 2014;13(9):893-903.
- The International League Against Epilepsy Consortium On Complex Epilepsies. Genome-wide mega-analysis identifies 11 new loci and highlights diverse biological mechanisms in the common epilepsies. *Nat Commun*. 2018;9:5269.
- Barkovich AJ, Dobyns WB, Guerrini R. Malformations of cortical development and epilepsy. *Cold Spring Harb Perspect Med*. 2015;5(5):a022392.
- Bell GS, Neligan A, Giavasi C, et al. Outcome of seizures in the general population after 25 years: a prospective follow-up, observational cohort study. *J Neurol Neurosurg Psychiatry*. 2016;87(8):843-850.
- Novy J, Bell GS, Peacock JL, Sisodiya SM, Sander JW. Epilepsy as a systemic condition: link with somatic comorbidities. *Acta Neurol Scand*. 2017;136(4):352-359.
- Klein P, Dingledine R, Aronica E, et al. Commonalities in epileptogenic processes from different acute brain insults: do they translate? *Epilepsia*. 2018;59(1):37-66.
- Whelan CD, Altmann A, Botía JA, et al. Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study. *Brain*. 2018;141(2):391-408.
- Vadlamudi L, Milne RL, Lawrence K, et al. Genetics of epilepsy: the testimony of twins in the molecular era. *Neurology*. 2014;83(12):1042-1048.
- Corey LA, Pellock JM, Kjeldsen MJ, Nakken KO. Importance of genetic factors in the occurrence of epilepsy syndrome type: a twin study. *Epilepsy Res*. 2011;97(1-2):103-111.
- Heidari M, Johnstone DM, Bassett B, et al. Brain iron accumulation affects myelin-related molecular systems implicated in a rare neurogenetic disease family with neuropsychiatric features. *Mol Psychiatry*. 2016;21(11):1599-1607.
- Zhang B, Gaiteri C, Bodea LG, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. *Cell*. 2013;153(3):707-720.
- Voineagu I, Wang X, Johnston P, et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. *Nature*. 2011;474(7351):380-384.
- Johnson MR, Shkura K, Langley SR, et al. Systems genetics identifies a convergent gene network for cognition and neurodevelopmental disease. *Nat Neurosci*. 2016;19(2):223-232.
- Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, et al. An anatomically comprehensive atlas of the adult human brain transcriptome. *Nature*. 2012;489(7416):391-399.
- Hawrylycz M, Miller JA, Menon V, et al. Canonical genetic signatures of the adult human brain. *Nat Neurosci*. 2015;18(12):1832-1844.
- Blanc F, Martinian L, Liagkouras I, Catarino C, Sisodiya SM, Thom M. Investigation of widespread neocortical pathology associated with hippocampal sclerosis in epilepsy: a postmortem study. *Epilepsia*. 2011;52(1):10-21.
- Frigerio F, Pasqualini G, Craparotta I, et al. n-3 docosapentaenoic acid-derived protectin D1 promotes resolution of neuroinflammation and arrests epileptogenesis. *Brain*. 2018;141(11):3130-3143.
- Jimenez-Mateos EM, Engel T, Merino-Serrais P, et al. Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. *Nat Med*. 2012;18(7):1087-1094.
- lori V, Iyer AM, Ravizza T, et al. Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy. *Neurobiol Dis*. 2017 Mar;99:12-23.
- Gu B, Huang YZ, He XP, Joshi RB, Jang W, McNamara JO. A peptide uncoupling BDNF receptor TrkB from phospholipase Cy1 prevents epilepsy induced by status epilepticus. *Neuron*. 2015;88(3):484-491.
- French L, Paus T. A FreeSurfer view of the cortical transcriptome generated from the Allen Human Brain Atlas. *Front Neurosci*. 2015;9:323.
- Menden K, Marouf M, Oller S, et al. Deep learning-based cell composition analysis from tissue expression profiles. *Sci Adv*. 2020;6(30):eaba2619.
- Weiner J 3rd, Domaszewska T. tmod: an R package for general and multivariate enrichment analysis. *PeerJ*. 2016;4:e2420v1. <https://doi.org/10.7287/peerj.preprints.2420v1>
- Devinsky O, Vezzani A, Najjar S, De Lanerolle NC, Rogawski MA. Glia and epilepsy: excitability and inflammation. *Trends Neurosci*. 2013;36(3):174-184.
- Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. *Nat Neurosci*. 2018;21(10):1359-1369.
- Srivastava PK, van Eyll J, Godard P, et al. A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target. *Nat Commun*. 2018;9(1):3561.
- Mathys H, Adaikkan C, Gao F, et al. Temporal tracking of microglia activation in neurodegeneration at single-cell resolution. *Cell Rep*. 2017;21(2):366-380.
- Holtman IR, Raj DD, Miller JA, et al. Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: a co-expression meta-analysis. *Acta Neuropathol Commun*. 2015;3(1):31.
- Grabert K, Michoel T, Karavolos MH, et al. Microglial brain region-dependent diversity and selective regional sensitivities to aging. *Nat Neurosci*. 2016;19(3):504-516.
- Fairfax BP, Humburg P, Makino S, et al. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. *Sci (New York, NY)*. 2014;343(6175):1246949.
- Elmore MRP, Najafi AR, Koike MA, et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. *Neuron*. 2014;82(2):380-397.
- Wilson DIG, Langston RF, Schlesiger MI, Wagner M, Watanabe S, Ainge JA. Lateral entorhinal cortex is critical for novel object-context recognition. *Hippocampus*. 2013;23(5):352-366.
- Delahaye-Duriez A, Srivastava P, Shkura K, et al. Rare and common epilepsies converge on a shared gene regulatory network providing opportunities for novel antiepileptic drug discovery. *Genome Biol*. 2016;17(1):245.
- Boer K, Spliet WGM, Van Rijen PC, Redeker S, Troost D, Aronica E. Evidence of activated microglia in focal cortical dysplasia. *J Neuroimmunol*. 2006;173(1-2):188-195.
- Aronica E, Gorter JA, Redeker S, et al. Distribution, characterization and clinical significance of microglia in glioneuronal tumours from

- patients with chronic intractable epilepsy. *Neuropathol Appl Neurobiol.* 2005;31(3):280-291.
37. Ravizza T, Gagliardi B, Noé F, Boer K, Aronica E, Vezzani A. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. *Neurobiol Dis.* 2008;29(1):142-160.
  38. Iyer A, Zurolo E, Spliet WGM, et al. Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias. *Epilepsia.* 2010;51(9):1763-1773.
  39. Ravizza T, Boer K, Redeker S, et al. The IL-1 $\beta$  system in epilepsy-associated malformations of cortical development. *Neurobiol Dis.* 2006;24(1):128-143.
  40. Morin-Brureau M, Millior G, Royer J, et al. Microglial phenotypes in the human epileptic temporal lobe. *Brain.* 2018;141(12):3343-3360.
  41. Boche D, Perry VH, Nicoll JAR. Activation patterns of microglia and their identification in the human brain. *Neuropathol Appl Neurobiol.* 2013;39(1):3-18.
  42. Hendrickx DAE, van Eden CG, Schuurman KG, Hamann J, Huitinga I. Staining of HLA-DR, Iba1 and CD68 in human microglia reveals partially overlapping expression depending on cellular morphology and pathology. *J Neuroimmunol.* 2017;309:12-22.
  43. Somani A, El-Hachami H, Patodia S, Sisodiya S, Thom M. Regional microglial populations in central autonomic brain regions in SUDEP. *Epilepsia.* 2021;62(6):1318-1328.
  44. Wu W, Li Y, Wei Y, et al. Microglia depletion aggravates the severity of acute and chronic seizures in mice. *Brain Behav Immun.* 2020;89:245-255.
  45. Weinhard L, Di Bartolomei G, Bolasco G, et al. Microglia remodel synapses by presynaptic trogocytosis and spine head filopodia induction. *Nat Commun.* 2018;9(1):1228.
  46. Caciagli L, Bernasconi A, Wiebe S, Koepp MJ, Bernasconi N, Bernhardt BC. A meta-analysis on progressive atrophy in intractable temporal lobe epilepsy: time is brain? *Neurology.* 2017;89(5):506-516.
  47. Blumcke I, Spreafico R, Haaker G, et al. Histopathological findings in brain tissue obtained during epilepsy surgery. *N Engl J Med.* 2017;377(17):1648-1656.
  48. Amhaoul H, Hamaide J, Bertoglio D, et al. Brain inflammation in a chronic epilepsy model: evolving pattern of the translocator protein during epileptogenesis. *Neurobiol Dis.* 2015;82:526-539.
  49. Gershen LD, Zanotti-Fregonara P, Dustin IH, et al. Neuroinflammation in temporal lobe epilepsy measured using positron emission tomographic imaging of translocator protein. *JAMA Neurol.* 2015;72(8):882-888.
  50. Butler T, Li Y, Tsui W, et al. Transient and chronic seizure-induced inflammation in human focal epilepsy. *Epilepsia.* 2016;57(9):e191-e194.
  51. Gupta N, Shyamasundar S, Patnala R, et al. Recent progress in therapeutic strategies for microglia-mediated neuroinflammation in neuropathologies. *Expert Opin Ther Targets.* 2018;22(9):765-781.

#### SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

**How to cite this article:** Altmann A, Ryten M, Di Nunzio M, et al. A systems-level analysis highlights microglial activation as a modifying factor in common epilepsies. *Neuropathol Appl Neurobiol.* 2021;1-15. doi:10.1111/nan.12758